cis-UCA
Asset
Cis-urocanic acid anti-inflammatory modulator for ocular surface indications.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Inflammation
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Dry eye syndrome
Phase 2, Completed, NCT02326090, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials1
- Evidence for its targets1
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 1 source